Exact Mass: 320.206
Exact Mass Matches: 320.206
Found 500 metabolites which its exact mass value is equals to given mass value 320.206,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
8-HETE
8(S)-HETE is a naturally occurring hydroxyeicosatetraenoic acid eicosanoid. 8(S)-HETE is a strong activator of peroxisome proliferator-activated receptors (PPARs) alpha and a weak activator of PPAR gamma. PPARs are nuclear hormone receptors that regulate gene transcription in response to peroxisome proliferators and fatty acids. PPARs also play an important role in the regulation of adipocyte differentiation. It is unclear however what naturally occurring compounds activate each of the PPAR subtypes. Additionally, 8(S)-HETE is able to induce differentiation of preadipocytes. (PMID: 7592593, 9113987) [HMDB] 8(S)-HETE is a naturally occurring hydroxyeicosatetraenoic acid eicosanoid. 8(S)-HETE is a strong activator of peroxisome proliferator-activated receptors (PPARs) alpha and a weak activator of PPAR gamma. PPARs are nuclear hormone receptors that regulate gene transcription in response to peroxisome proliferators and fatty acids. PPARs also play an important role in the regulation of adipocyte differentiation. It is unclear however what naturally occurring compounds activate each of the PPAR subtypes. Additionally, 8(S)-HETE is able to induce differentiation of preadipocytes. (PMID: 7592593, 9113987).
20-Hydroxyeicosatetraenoic acid
20-Hydroxyeicosatetraenoic acid (20-HETE) is a metabolite of arachidonic acid. Cytochrome P450 enzymes of the 4A and 4F families catalyze the omega-hydroxylation of arachidonic acid and produce 20-HETE. 20-HETE is a potent constrictor of renal, cerebral, and mesenteric arteries. The vasoconstrictor response to 20-HETE is associated with activation of protein kinase, Rho kinase, and the mitogen-activated protein (MAP) kinase pathway C. 20-HETE also increases intracellular Ca2+ by causing the depolarization of vascular smooth muscle membrane secondary to blocking the large-conductance Ca2+-activated K+-channels and by a direct effect on L-type Ca channels. Elevations in the production of 20-HETE mediate the myogenic response of skeletal, renal, and cerebral arteries to elevations in transmural pressure. There is an important interaction between nitric oxide (NO) and the formation of 20-HETE production. NO inhibits the formation of 20-HETE formation in renal and cerebral arteries. A fall in levels of 20-HETE contributes to the cyclic GMP-independent dilator effect of NO to activate the large-conductance Ca2+-activated K+-channels and to dilate the cerebral arteries (PMID: 16258232). Metabolite produced during NADPH dependent enzymatic oxidation of arachidonic acid. Potent vasoconstrictor [CCD]
11,12-Epoxyeicosatrienoic acid
11,12-Epoxyeicosatrienoic acid (CAS: 81276-02-0) is an epoxyeicosatrienoic acid (EET). Induction of CYP2C8 in native coronary artery endothelial cells by beta-naphthoflavone enhances the formation of 11,12-epoxyeicosatrienoic acid, as well as endothelium-derived hyperpolarizing factor-mediated hyperpolarization and relaxation. Transfection of coronary arteries with CYP2C8 antisense oligonucleotides resulted in decreased levels of CYP2C and attenuated the endothelium-derived hyperpolarizing factor-mediated vascular responses. Thus, a CYP-epoxygenase product is an essential component of the endothelium-derived hyperpolarizing factor-mediated relaxation in the porcine coronary artery, and CYP2C8 fulfills the criteria for the coronary endothelium-derived hyperpolarization factor synthase. The role of EETs in the regulation of the cerebral circulation has become more important since it was realized that EETs are produced in another specialized cell type of the brain, the astrocytes. It has become evident that EETs released from astrocytes may mediate cerebral functional hyperemia. Molecular and pharmacological evidence has shown that neurotransmitter release and spillover onto astrocytes can generate EETs. Since these EETs may reach the vasculature via astrocyte foot-processes, they have the same potential as their endothelial counterparts to hyperpolarize and dilate cerebral vessels. P450 enzymes contain heme in their catalytic domain and nitric oxide (NO) appears to bind to these heme moieties and block formation of P450 products, including EETs. Thus, there appears to be crosstalk between P450 enzymes and NO/NO synthase. The role of fatty acid metabolites and cerebral blood flow becomes even more complex in light of data demonstrating that cyclooxygenase products can act as substrates for P450 enzymes (PMID: 17494091, 17434916, 17406062, 17361113, 15581597, 11413051, 10519554). EETs function as autocrine and paracrine mediators. During inflammation, a large amount of arachidonic acid (AA) is released into the cellular milieu and cyclooxygenase enzymes convert this AA to prostaglandins that in turn sensitize pain pathways. However, AA is also converted into natural EETs by cytochrome P450 enzymes. Cytochrome P450 (CYP) epoxygenases convert arachidonic acid into four epoxyeicosatrienoic acid (EET) regioisomers, 5,6-, 8,9-, 11,12-, and 14,15-EET. EETs produce vascular relaxation by activating smooth muscle large-conductance Ca2+-activated K+ channels. In particular, 11,12-epoxy-5Z,8Z,14Z-eicosatrienoic acid has been shown to play a role in the recovery of depleted Ca2+ pools in cultured smooth muscle cells (PMID: 9368016). In addition, EETs have anti-inflammatory effects on blood vessels and in the kidney, promote angiogenesis, and protect ischemic myocardium and the brain. EET levels are typically regulated by soluble epoxide hydrolase (sEH), the major enzyme degrading EETs. Specifically, soluble epoxide hydrolase (sEH) converts EETs into dihydroxyeicosatrienoic acids. 11,12-EpETrE or 11,12-epoxy-5Z,8Z,14Z-eicosatrienoic acid is an epoxyeicosatrienoic acid or an EET derived from arachadonic acid. EETs function as autacrine and paracrine mediators. During inflammation, a large amount of arachidonic acid (AA) is released into the cellular milieu and cyclooxygenase enzymes convert this AA to prostaglandins that in turn sensitize pain pathways. However, AA is also converted to natural epoxyeicosatrienoic acids (EETs) by cytochrome P450 enzymes. Cytochrome P450 (CYP) epoxygenases convert arachidonic acid to four epoxyeicosatrienoic acid (EET) regioisomers, 5,6-, 8,9-, 11,12-, and 14,15-EET. EETs produce vascular relaxation by activating smooth muscle large-conductance Ca2+-activated K+ channels. In particular, 11,12-epoxy-5Z,8Z,14Z-eicosatrienoic acid has been show to play a role in the recovery of depleted Ca2+ pools in cultured smooth muscle cells (PMID: 9368016). In addition, EETs have antiinflammatory effects on blood vessels and in the kidney, promote angiogenesis, and protect ischemic myocardium and brain. EET levels are typically regulated by soluble epoxide hydrolase (sEH), the major enzyme degrading EETs. Specifically, soluble epoxide hydrolase (sEH) converts EETs to dihydroxyeicosatrienoic acids. [HMDB] D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
Iprovalicarb
CONFIDENCE standard compound; EAWAG_UCHEM_ID 2936 EAWAG_UCHEM_ID 2936; CONFIDENCE standard compound CONFIDENCE standard compound; INTERNAL_ID 482; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9259; ORIGINAL_PRECURSOR_SCAN_NO 9255 CONFIDENCE standard compound; INTERNAL_ID 482; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9307; ORIGINAL_PRECURSOR_SCAN_NO 9306 CONFIDENCE standard compound; INTERNAL_ID 482; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9221; ORIGINAL_PRECURSOR_SCAN_NO 9219 CONFIDENCE standard compound; INTERNAL_ID 482; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9260; ORIGINAL_PRECURSOR_SCAN_NO 9257 CONFIDENCE standard compound; INTERNAL_ID 482; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9324; ORIGINAL_PRECURSOR_SCAN_NO 9321 CONFIDENCE standard compound; INTERNAL_ID 482; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9303; ORIGINAL_PRECURSOR_SCAN_NO 9301
16(R)-HETE
16(R)-HETE is a metabolite of arachidonic acid, metabolized by the enzyme Cytochrome P450, family 2, subfamily C [EC:1.14.13.80 1.14.13.48 1.14.13.49]. 16(R)-HETE is an endogenous lipidic inhibitor of human neutrophil inhibitor of adhesion and aggregation activity. Human polymorphonuclear leukocytes (PMNs) produce 16(R)-HETE that modulates their function. HETEs have different biological properties based on sites of production and can be stored in tissue lipids and released in response to hormonal stimuli. Eicosanoids generated during the actions of growth factors and vasoconstrictors can modulate disease processes by affecting vascular homeostasis, inflammation, cellular growth, apoptosis and oxidant stress. In lung, the presence of these eicosanoids in the pulmonary vasculature and airways, including effects on pulmonary vascular and bronchial smooth muscle tone and airway epithelial ion transport. (PMID: 16258232, 14626496, 12681244, 11123211, 14552765, 11126912) [HMDB] 16(R)-HETE is a metabolite of arachidonic acid, metabolized by the enzyme Cytochrome P450, family 2, subfamily C [EC:1.14.13.80 1.14.13.48 1.14.13.49]. 16(R)-HETE is an endogenous lipidic inhibitor of human neutrophil inhibitor of adhesion and aggregation activity. Human polymorphonuclear leukocytes (PMNs) produce 16(R)-HETE that modulates their function. HETEs have different biological properties based on sites of production and can be stored in tissue lipids and released in response to hormonal stimuli. Eicosanoids generated during the actions of growth factors and vasoconstrictors can modulate disease processes by affecting vascular homeostasis, inflammation, cellular growth, apoptosis and oxidant stress. In lung, the presence of these eicosanoids in the pulmonary vasculature and airways, including effects on pulmonary vascular and bronchial smooth muscle tone and airway epithelial ion transport. (PMID: 16258232, 14626496, 12681244, 11123211, 14552765, 11126912).
19(S)-HETE
19(S)-HETE is an intermediate in Arachidonic acid metabolism. 19(S)-HETE is converted from Arachidonic acid via the enzyme CYP2U and Unspecific. Monooxygenase. (EC:1.14.14.1). 19(S)-HETE is an intermediate in Arachidonic acid metabolism. 19(S)-HETE is converted from Arachidonic acid via the enzyme CYP2U and Unspecific
14,15-Epoxy-5,8,11-eicosatrienoic acid
14,15-epoxy-5,8,11-eicosatrienoic acid is an epoxyeicosatrienoic acid (EET), a metabolite of arachidonic acid. The P450 eicosanoids epoxyeicosatrienoic acids (EETs) are endogenous lipid mediators produced by P450 epoxygenases and metabolized through multiple pathways including soluble epoxide hydrolase (sEH). The cytochrome P-450 (P450) monooxygenase pathway includes enzymes of the CYP1A, CYP2B, CYP2C, CYP2E, and CYP2J subfamilies that catalyze the formation of four regioisomeric products, 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid. EETs are produced in brain and perform important biological functions, including protection from ischemic injury. Both light flashes and direct glial stimulation produce vasodilatation mediated by EETs. EETs may be involved in the development of hypertension and endothelial dysfunction in DOCA-salt rats, but not in excessive collagen deposition or electrophysiological abnormalities. EETs have vasodilator and natriuretic effect. Blockade of EET formation is associated with salt-sensitive hypertension. Four regioisomeric cis-EET are primary products of arachidonic acid metabolism by cytochrome P450 epoxygenases. Upon hydration by soluble epoxide hydrolase (sEH), EET are metabolized to dihydroxyeicosatrienoic acids (DHET). These hydration products are more stable and less biologically active than EETs. (PMID: 17494091, 17468203, 17434916, 17406062, 17361113, 15581597). 14,15-epoxy-5,8,11-eicosatrienoic acid is an epoxyeicosatrienoic acid (EET), a metabolite of arachidonic acid. D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
8,9-Epoxyeicosatrienoic acid
8,9-Epoxyeicosatrienoic acid is an epoxyeicosatrienoic acid eicosanoid, a metabolite of arachidonic acid. The P450 epoxyeicosatrienoic acids (EETs) are endogenous lipid mediators produced by P450 epoxygenases and metabolized through multiple pathways including soluble epoxide hydrolase (sEH). The cytochrome P-450 (P450) monooxygenase pathway includes enzymes of the CYP1A, CYP2B, CYP2C, CYP2E, and CYP2J subfamilies that catalyze the formation of four regioisomeric products, 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid. EETs are produced in brain and perform important biological functions, including protection from ischemic injury. Both light flashes and direct glial stimulation produce vasodilatation mediated by EETs. EETs may be involved in the development of hypertension and endothelial dysfunction in DOCA-salt rats, but not in excessive collagen deposition or electrophysiological abnormalities. EETs have vasodilator and natriuretic effect. Blockade of EET formation is associated with salt-sensitive hypertension. Four regioisomeric cis-EET are primary products of arachidonic acid metabolism by cytochrome P450 epoxygenases. Upon hydration by soluble epoxide hydrolase (sEH), EET are metabolized to dihydroxyeicosatrienoic acids (DHET). These hydration products are more stable and less biologically active than EETs. (PMID: 17494091, 17468203, 17434916, 17406062, 17361113, 15581597) [HMDB] 8,9-Epoxyeicosatrienoic acid is an epoxyeicosatrienoic acid eicosanoid, a metabolite of arachidonic acid. The P450 epoxyeicosatrienoic acids (EETs) are endogenous lipid mediators produced by P450 epoxygenases and metabolized through multiple pathways including soluble epoxide hydrolase (sEH). The cytochrome P-450 (P450) monooxygenase pathway includes enzymes of the CYP1A, CYP2B, CYP2C, CYP2E, and CYP2J subfamilies that catalyze the formation of four regioisomeric products, 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid. EETs are produced in brain and perform important biological functions, including protection from ischemic injury. Both light flashes and direct glial stimulation produce vasodilatation mediated by EETs. EETs may be involved in the development of hypertension and endothelial dysfunction in DOCA-salt rats, but not in excessive collagen deposition or electrophysiological abnormalities. EETs have vasodilator and natriuretic effect. Blockade of EET formation is associated with salt-sensitive hypertension. Four regioisomeric cis-EET are primary products of arachidonic acid metabolism by cytochrome P450 epoxygenases. Upon hydration by soluble epoxide hydrolase (sEH), EET are metabolized to dihydroxyeicosatrienoic acids (DHET). These hydration products are more stable and less biologically active than EETs. (PMID: 17494091, 17468203, 17434916, 17406062, 17361113, 15581597). D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
11(R)-HETE
11(R)-HETE is produced from arachidonic acid by both COX-1 and COX-2 (cyclooxygenases). Using a model of intestinal epithelial cells that express the COX-2 permanently, 11(R)-HETE is produced upon stimulation. However, 11(R)-HETE is not detected in intact cells. Endothelial cells release several factors which influence vascular tone, leukocyte function and platelet aggregation; 11(R)-HETE is one of these factors. (PMID: 15964853, 8555273) [HMDB] 11(R)-HETE is produced from arachidonic acid by both COX-1 and COX-2 (cyclooxygenases). Using a model of intestinal epithelial cells that express the COX-2 permanently, 11(R)-HETE is produced upon stimulation. However, 11(R)-HETE is not detected in intact cells. Endothelial cells release several factors which influence vascular tone, leukocyte function and platelet aggregation; 11(R)-HETE is one of these factors. (PMID: 15964853, 8555273).
5,6-Epoxy-8,11,14-eicosatrienoic acid
5,6-Epoxy-8,11,14-eicosatrienoic acid is an Epoxyeicosatrienoic acid (EET), a metabolite of arachidonic acid. The epoxyeicosatrienoic acids (EETs) are endogenous lipid mediators produced by P450 epoxygenases and metabolized through multiple pathways including soluble epoxide hydrolase (sEH). The cytochrome P-450 (P450) monooxygenase pathway includes enzymes of the CYP1A, CYP2B, CYP2C, CYP2E, and CYP2J subfamilies that catalyze the formation of four regioisomeric products, 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid. EETs are produced in brain and perform important biological functions, including protection from ischemic injury. Both light flashes and direct glial stimulation produce vasodilatation mediated by EETs. EETs may be involved in the development of hypertension and endothelial dysfunction in DOCA-salt rats, but not in excessive collagen deposition or electrophysiological abnormalities. EETs have vasodilator and natriuretic effect. Blockade of EET formation is associated with salt-sensitive hypertension. (PMID: 17494091, 17468203, 17434916, 17406062, 17361113) [HMDB] 5,6-Epoxy-8,11,14-eicosatrienoic acid is an Epoxyeicosatrienoic acid (EET), a metabolite of arachidonic acid. The epoxyeicosatrienoic acids (EETs) are endogenous lipid mediators produced by P450 epoxygenases and metabolized through multiple pathways including soluble epoxide hydrolase (sEH). The cytochrome P-450 (P450) monooxygenase pathway includes enzymes of the CYP1A, CYP2B, CYP2C, CYP2E, and CYP2J subfamilies that catalyze the formation of four regioisomeric products, 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid. EETs are produced in brain and perform important biological functions, including protection from ischemic injury. Both light flashes and direct glial stimulation produce vasodilatation mediated by EETs. EETs may be involved in the development of hypertension and endothelial dysfunction in DOCA-salt rats, but not in excessive collagen deposition or electrophysiological abnormalities. EETs have vasodilator and natriuretic effect. Blockade of EET formation is associated with salt-sensitive hypertension. (PMID: 17494091, 17468203, 17434916, 17406062, 17361113).
3-hydroxy-16-(hydroxymethyl)androstan-17-one
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one
4,5alpha-Dihydro-11beta-hydroxy-17-methyltestosterone
2-((2E)-3,7-Dimethyl-2,6-octadienyl)-5,6-dimethoxy-3-methyl-1,4-benzenediol
2-Hydroxy-6-tridecylbenzoic acid
2-Hydroxy-6-tridecylbenzoic acid is a hydroxybenzoic acid. It is functionally related to a salicylic acid. 2-Hydroxy-6-tridecylbenzoic acid is a natural product found in Ginkgo biloba and Caulocystis cephalornithos with data available. 2-Hydroxy-6-tridecylbenzoic acid is found in fats and oils. 2-Hydroxy-6-tridecylbenzoic acid is isolated from pistachio shells. 2-Hydroxy-6-tridecylbenzoic acid is isolated from Ginkgo biloba (ginkgo). Isolated from pistachio shells. Isolated from Ginkgo biloba (ginkgo). 2-Hydroxy-6-tridecylbenzoic acid is found in fats and oils and nuts. D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates Ginkgolic Acid (C13:0) is a natural anticariogenic agent in that it exhibits antimicrobial activity against S. mutans and suppresses the specific virulence factors associated with its cariogenicity. IC50 value: Inhibiting the biofilm formation of S. mutans (MBIC (50) = 4 μg/mL); reduced 1-day-developed biofilm of S. mutans by 50 \\% or more at low concentration (MBRC (50) = 32 μg/mL). Target: In vitro: Ginkgolic Acid (C13:0) inhibited not only the growth of S. mutans planktonic cells at minimum inhibitory concentration (MIC) of 4 μg/mL and minimum bactericidal concentration (MBC) of 8 μg/mL but also the acid production and adherence to saliva-coated hydroxyapatite of S. mutans at sub-MIC concentration. In addition, this agent was effective in inhibiting the biofilm formation of S. mutans (MBIC (50) = 4 μg/mL), and it reduced 1-day-developed biofilm of S. mutans by 50 \\% or more at low concentration (MBRC (50) = 32 μg/mL). Furthermore Ginkgolic Acid (C13:0) disrupted biofilm integrity effectively [1]. In vivo: Ginkgolic Acid (C13:0) is a natural anticariogenic agent in that it exhibits antimicrobial activity against S. mutans and suppresses the specific virulence factors associated with its cariogenicity. IC50 value: Inhibiting the biofilm formation of S. mutans (MBIC (50) = 4 μg/mL); reduced 1-day-developed biofilm of S. mutans by 50 \% or more at low concentration (MBRC (50) = 32 μg/mL). Target: In vitro: Ginkgolic Acid (C13:0) inhibited not only the growth of S. mutans planktonic cells at minimum inhibitory concentration (MIC) of 4 μg/mL and minimum bactericidal concentration (MBC) of 8 μg/mL but also the acid production and adherence to saliva-coated hydroxyapatite of S. mutans at sub-MIC concentration. In addition, this agent was effective in inhibiting the biofilm formation of S. mutans (MBIC (50) = 4 μg/mL), and it reduced 1-day-developed biofilm of S. mutans by 50 \% or more at low concentration (MBRC (50) = 32 μg/mL). Furthermore Ginkgolic Acid (C13:0) disrupted biofilm integrity effectively [1]. In vivo:
18-Hydroxyarachidonic acid
(18R)-Hydroxyarachidonate is a substrate for CYP4F8 or leukotriene-B4 20-monooxygenase (EC 1.14.13.30). This enzyme hydroxylates arachdonic acid (20:4n-6) to (18R)-hydroxyarachidonate in the endoplasmic reticulum. This reaction is irreversible. CYP4F8 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and functions as a 19-hydroxylase of prostaglandins in seminal vesicles. In particular, CYP4F8 catalyzes the 2-hydroxylation of PGH1 and PGH2, which will lead to biosynthesis of the two main PGs of human seminal fluid, (19R)-hydroxy-PGE1 and (19R)-hydroxy-PGE2 (PMID: 10791960). 18-Hydroxyarachidonic acid is an intermediate in eicosanoid metabolism. [HMDB] (18R)-Hydroxyarachidonate is a substrate for CYP4F8 or leukotriene-B4 20-monooxygenase (EC 1.14.13.30). This enzyme hydroxylates arachdonic acid (20:4n-6) to (18R)-hydroxyarachidonate in the endoplasmic reticulum. This reaction is irreversible. CYP4F8 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and functions as a 19-hydroxylase of prostaglandins in seminal vesicles. In particular, CYP4F8 catalyzes the 2-hydroxylation of PGH1 and PGH2, which will lead to biosynthesis of the two main PGs of human seminal fluid, (19R)-hydroxy-PGE1 and (19R)-hydroxy-PGE2 (PMID: 10791960). 18-Hydroxyarachidonic acid is an intermediate in eicosanoid metabolism.
17-HETE
Electrolyte and fluid transport in the kidney are regulated in part by arachidonic acid and its metabolites. (?)17-HETE is the racemic version of a cytochrome P450 (CYP450) metabolite of arachidonic acid that has stereospecific effects on sodium transport in the kidney. At a concentration of 2 ?M the (S)-enantiomer of 17-HETE inhibits proximal tubule ATPase activity by as much as 70\\%, whereas the (R)-isomer is inactive [HMDB] Electrolyte and fluid transport in the kidney are regulated in part by arachidonic acid and its metabolites. (±)17-HETE is the racemic version of a cytochrome P450 (CYP450) metabolite of arachidonic acid that has stereospecific effects on sodium transport in the kidney. At a concentration of 2 ¬µM the (S)-enantiomer of 17-HETE inhibits proximal tubule ATPase activity by as much as 70\\%, whereas the (R)-isomer is inactive.
14R,15S-EpETrE
14R,15S-EpETrE is the dominant extracellular metabolite of epoxygenase products of arachidonic acid released from human luteinised granulosa cells. Epoxyeicosatrienoic acids (EpETrEs) have been reported recently having vasodilatory effects and a role of P-450-dependent arachidonic acid monooxygenase metabolites is suggested in vasoregulation. The physiological role of this compound has not been totally established, although in other tissues EpETrEs are mainly involved in hormone production and in the vascular and renal systems. Some studies have implicated epoxygenase metabolites of arachidonic acid in the control of steroidogenesis in luteinised granulosa cells. (PMID: 12749593, 12361727, 1650001) [HMDB] 14R,15S-EpETrE is the dominant extracellular metabolite of epoxygenase products of arachidonic acid released from human luteinised granulosa cells. Epoxyeicosatrienoic acids (EpETrEs) have been reported recently having vasodilatory effects and a role of P-450-dependent arachidonic acid monooxygenase metabolites is suggested in vasoregulation. The physiological role of this compound has not been totally established, although in other tissues EpETrEs are mainly involved in hormone production and in the vascular and renal systems. Some studies have implicated epoxygenase metabolites of arachidonic acid in the control of steroidogenesis in luteinised granulosa cells. (PMID: 12749593, 12361727, 1650001). D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
[8]-Gingerdione
[8]-Gingerdione is found in herbs and spices. [8]-Gingerdione is a constituent of Zingiber officinale (ginger). Constituent of Zingiber officinale (ginger). [8]-Gingerdione is found in herbs and spices.
(ent-2alpha,3beta,15beta)-16-Kaurene-2,3,15-triol
(ent-2alpha,3beta,15beta)-16-Kaurene-2,3,15-triol is found in cereals and cereal products. (ent-2alpha,3beta,15beta)-16-Kaurene-2,3,15-triol is isolated from leaves of a blight-resistant rice cultivar. Isolated from leaves of a blight-resistant rice cultivariety (ent-2alpha,3beta,15beta)-16-Kaurene-2,3,15-triol is found in cereals and cereal products.
10-Acetylpanaxytriol
10-Acetylpanaxytriol is found in tea. 10-Acetylpanaxytriol is found in ginseng roots. Found in ginseng roots
8alpha,13R-Epoxy-14-labden-19-oic acid
8alpha,13R-Epoxy-14-labden-19-oic acid is isolated from Pinus sylvestris (Scotch pine). Isolated from Pinus sylvestris (Scotch pine)
Oryzalide A
Oryzalide A is found in cereals and cereal products. Oryzalide A is isolated from rice leaves. Isolated from rice leaves. Oryzalide A is found in cereals and cereal products.
(ent-2alpha,3beta,15beta,16beta)-15,16-Epoxy-2,3-kauranediol
(ent-2alpha,3beta,15beta,16beta)-15,16-Epoxy-2,3-kauranediol is found in cereals and cereal products. (ent-2alpha,3beta,15beta,16beta)-15,16-Epoxy-2,3-kauranediol is isolated from leaves of a blight-resistant rice cultivar. Isolated from leaves of a blight-resistant rice cultivariety ent-15b,16b-Epoxy-2a,3b-kauranediol is found in cereals and cereal products.
Annoglabasin E
Annoglabasin E is found in alcoholic beverages. Annoglabasin E is a constituent of Annona glabra (pond apple) Constituent of Annona glabra (pond apple). Annoglabasin E is found in alcoholic beverages and fruits.
Oryzalide B
Oryzalide B is found in cereals and cereal products. Oryzalide B is isolated from rice leaves. Isolated from rice leaves. Oryzalide B is found in cereals and cereal products.
Crispane
Crispane is found in herbs and spices. Crispane is isolated from Lasianthaea fruticosa and parsley Petroselinum crispum [DFC] (Yannai, Shmuel. (2004) Dictionary of food compounds with CD-ROM: Additives, flavors, and ingredients. Boca Raton: Chapman & Hall/CRC.). Isolated from Lasianthaea fruticosa and parsley Petroselinum crispum [DFC]. Crispane is found in herbs and spices and parsley.
5'-Carboxy-alpha-chromanol
5-carboxy-alpha-tocopherol is a dehydrogenation carboxylate product of 5-hydroxy-a-tocopherol by an unidentified microsomal enzyme(s) probably via an aldehyde intermediate. The tocopherols ( a-tocopherol , b-tocopherol ,r-tocopherol and d-tocopherol ) and their corresponding tocotrienols are synthesized by plants and have vitamin E antixoidant activity (see pathway vitamin E biosynthesis ). They differ in the number and location of methyl groups on the chromanol ring. The naturally occurring form of a-tocopherol is (2R,4R,8R)-a-tocopherol (synonym (R,R,R)-a-tocopherol). Synthetic a-tocopherols are a racemic mixture of eight different R and S stereoisomers. Only the 2R forms are recognized as meeting human requirements. The in vivo function of vitamin E is to scavenge peroxyl radicals via its phenolic (chromanol) hydroxyl group, thus protecting lipids against free radical-catalyzed peroxidation. The tocopheryl radical formed can then be reduced by reductants such as L-ascorbate. Other major products of a-tocopherol oxidation include α-tocopherylquinone and epoxy-a-tocopherols. The metabolites a-tocopheronic acid and its lactone, known as the Simon metabolites, are generally believed to be artefacts. In addition to these oxidation products, the other major class of tocopherol metabolites is the carboxyethyl-hydroxychromans.These metabolites are produced in significant amounts in response to excess vitamin E ingestion. Vitamin E is fat-soluble and its utilization requires intestinal fat absorption mechanisms. It is secreted from the intestine into the lymphatic system in chylomicrons which subsequently enter the plasma. Lipolysis of these chylomicrons can result in delivery of vitamin E to tissues, transfer to high-density lipoproteins (and subsequently to other lipoproteins via the phospholipid exchange protein), or retention in chylomicron remnants. These remnants are taken up by the liver. Natural (R,R,R)-α-tocopherol and synthetic 2R-α-tocopherols are then preferentially secreted from the liver into plasma as a result of the specificity of the α-tocopherol transfer protein. This protein, along with the metabolism of excess vitamin E in the liver and excretion into urine and bile, mediate the supply of a-tocopherol in plasma and tissues. 5-carboxy-alpha-tocopherol is a dehydrogenation carboxylate product of 5-hydroxy-a-tocopherol by an unidentified microsomal enzyme(s) probably via an aldehyde intermediate
13-HETE
13-Hydroxyeicosatetraenoic acid is one of the main metabolites of 15-lipoxygenases (15-LOXs), are endogenous ligands of PPARr. It can inhibit cell proliferation and induce apoptosis in several types of human cancer. 13-HETE is an arachidonic acid metabolite in rat liver microsomes, and is a metabolite of red algae.Hydroxyeicosatetraenoic acids (HETEs) are formed in numerous cell types by enzymatically-mediated hydroxylation of arachidonic acid. There are three distinct enzymes involved in HETE biosynthesis:lipoxygenase (LOX), prostaglandin H (PGH) synthase, and cytochrome P-450. LOX- and PGH-synthase-mediated arachidonic acid metabolism is normally highly stereoselective. 13-Hydroxyeicosatetraenoic acid is one of the main metabolites of 15-lipoxygenases (15-LOXs), are endogenous ligands of PPARr. It can inhibit cell proliferation and induce apoptosis in several types of human cancer
12 Hydroxy arachidonic acid
This compound belongs to the family of Hydroxyeicosatetraenoic Acids. These are eicosanoic acids with an attached hydroxyl group and four CC double bonds.......
10-HETE
10-HETE is a HETE(Hydroxyeicosatetraenoic acid)with the hydroxy group located in C-10 position. The HETE metabolites are identified as omega-hydroxy derivatives and 10-HETE is one of the major products of NADPH-dependent arachidonic acid metabolism in rat liver microsomes. The conversion of arachidonic acid to HETE can be catalyzed via lipoxygenase ,cyclooxygenase or P-450 dependent route. [PMID: 7646075]. 10-HETE is a HETE(Hydroxyeicosatetraenoic acid)with the hydroxy group located in C-10 position. The HETE metabolites are identified as omega-hydroxy derivatives and 10-HETE is one of the major products of NADPH-dependent arachidonic acid metabolism in rat liver microsomes. The conversion of arachidonic acid to HETE can be catalyzed via lipoxygenase ,cyclooxygenase or P-450 dependent route.
12S-hydroxy-5E,8Z,10Z,14Z-eicosatetraenoic acid
12S-hydroxy-5E,8Z,10Z,14Z-eicosatetraenoic acid, also known as 12-S-HETE or Acid, 12-S-hydroxyeicosatetraenoic, is classified as a member of the Hydroxyeicosatetraenoic acids. Hydroxyeicosatetraenoic acids are eicosanoic acids with an attached hydroxyl group and four CC double bonds. 12S-hydroxy-5E,8Z,10Z,14Z-eicosatetraenoic acid is considered to be practically insoluble (in water) and acidic. 12S-hydroxy-5E,8Z,10Z,14Z-eicosatetraenoic acid is an eicosanoid lipid molecule
15R-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid
15R-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid is also known as 15R-HETE. 15R-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid is considered to be practically insoluble (in water) and acidic. 15R-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid is an eicosanoid lipid molecule
18-Hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid
18-Hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid is an eicosanoid lipid molecule. It is classified as a member of the hydroxyeicosatetraenoic acids. Hydroxyeicosatetraenoic acids are eicosanoic acids with an attached hydroxyl group and four CC double bonds. 18-Hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid is considered to be practically insoluble (in water) and acidic.
7-HETE
7-HETE, also known as 7-Hydroxyeicosatetraenoic acid, is classified as a member of the Hydroxyeicosatetraenoic acids. Hydroxyeicosatetraenoic acids are eicosanoic acids with an attached hydroxyl group and four CC double bonds. 7-HETE is considered to be practically insoluble (in water) and acidic
8-hydroxy-5Z,9E,11Z,14Z-eicosatetraenoic acid
8-hydroxy-5Z,9E,11Z,14Z-eicosatetraenoic acid is also known as 8-Hydroxyeicosatetraenoic acid, (e,Z,Z,Z)-isomer. 8-hydroxy-5Z,9E,11Z,14Z-eicosatetraenoic acid is considered to be practically insoluble (in water) and acidic. 8-hydroxy-5Z,9E,11Z,14Z-eicosatetraenoic acid is an eicosanoid lipid molecule
12,15-Epoxy-13,14-dimethyloctadeca-10,12,14-trienoic acid
12,15-Epoxy-13,14-dimethyloctadeca-10,12,14-trienoic acid is an unsaturated furan fatty acid (F-acid). F-acids are heterocyclic fatty acids containing a central furan moiety with a carboxylalkyl chain (mostly 7, 9, 11, or 13 carbons) in the 2-position and an alkyl chain (mostly 3 or 5 carbons) in the 5-position. Despite being found in low concentrations in food lipids, they are excellent antixoxidants and radical scavengers. This allows them to play an important role in preventing lipid peroxidation and protecting polyunsaturated fatty acids. They are often incorporated into phospholipids and cholesterol esters of fish and other marine organisms. 12,15-Epoxy-13,14-dimethyloctadeca-10,12,14-trienoic acid, in particular, can be described by the shorthand notation 11D3:1. This refers to its 11-carbon carboxyalkenyl moiety, the dimethyl substitutions in the 3- and 4-positions of its furan moiety, and its 3-carbon alkyl moiety. It has been identified in the fish liver.
12,15-Epoxy-13,14-dimethyloctadeca-12,14,16-trienoic acid
12,15-Epoxy-13,14-dimethyloctadeca-12,14,16-trienoic acid is an unsaturated furan fatty acid (F-acid). F-acids are heterocyclic fatty acids containing a central furan moiety with a carboxylalkyl chain (mostly 7, 9, 11, or 13 carbons) in the 2-position and an alkyl chain (mostly 3 or 5 carbons) in the 5-position. Despite being found in low concentrations in food lipids, they are excellent antixoxidants and radical scavengers. This allows them to play an important role in preventing lipid peroxidation and protecting polyunsaturated fatty acids. They are often incorporated into phospholipids and cholesterol esters of fish and other marine organisms. 12,15-Epoxy-13,14-dimethyloctadeca-12,14,16-trienoic acid, in particular, can be described by the shorthand notation 11D3:1. This refers to its 11-carbon carboxyalkyl moiety, the dimethyl substitutions in the 3- and 4-positions of its furan moiety, and its 3-carbon alkenyl moiety. It has been identified in the fish liver.
(14R,15S)-14,15-Epoxy-5,8,11-icosatrienoic acid
14,15-epoxy-5,8,11-eicosatrienoic acid is an epoxyeicosatrienoic acid (EET), a metabolite of arachidonic acid. D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
11-Meo-fes
(5E,8E,11E,14E)-19-Hydroxyicosa-5,8,11,14-tetraenoic acid
11-Hydroxy-5Z,8Z,11E,14Z-eicosatetraenoic acid
12(S)-Hydroxy-5,8,10,14-eicosatetraenoic acid
12-hydroxyeicosatetraenoic acid (12-HETE) is an eicosanoid, a 5-lipoxygenase metabolite of arachidonic acid. 5-Lipoxygenase (LO)-derived leukotrienes are involved in inflammatory glomerular injury. LO product 12-HETE is associated with pathogenesis of hypertension, and may mediate angiotensin II and TGFbeta induced mesengial cell abnormality in diabetic nephropathy. 12-HETE is markedly elevated in the psoriatic lesions. 12-HETE is a vasoconstrictor eicosanoid that contribute to high blood pressure in (renovascular) hypertension and pregnancy-induced hypertension. A significant percentage of patients suffering from a selective increase in plasma LDL cholesterol (type IIa hyperlipoproteinaemia) exhibits increased platelet reactivity. This includes enhanced platelet responsiveness against a variety of platelet-stimulating agents ex vivo and enhanced arachidonic acid metabolism associated with increased generation of arachidonic acid metabolites such as 12-HETE, and secretion of platelet-storage products. (PMID: 7562532, 12480795, 17361113, 8498970,1333255, 2119633). 12-HETE is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-s-HETE analog has been reported to augment tumour cell metastatic potential through activation of protein kinase c. 12-HETE can be formed either in the 12-S or 12-R configuration. It has a diversity of biological actions and is generated by a number of tissues including the renal glomerulus and the vasculature. 12-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. 12-HETE is a neuromodulator that is synthesized during ischemia. Its neuronal effects include attenuation of calcium influx and glutamate release as well as inhibition of AMPA receptor (AMPA-R) activation. 12-HETE is found in corn.
15-Hydroxy-5,8,11,13-eicosatetraenoic acid
4-[3-(Tetradeca-2,5,8-trien-1-yl)oxiran-2-yl]butanoic acid
5,6-Epoxy-8,11,14-eicosatrienoic acid is an Epoxyeicosatrienoic acid (EET), a metabolite of arachidonic acid. The epoxyeicosatrienoic acids (EETs) are endogenous lipid mediators produced by P450 epoxygenases and metabolized through multiple pathways including soluble epoxide hydrolase (sEH). The cytochrome P-450 (P450) monooxygenase pathway includes enzymes of the CYP1A, CYP2B, CYP2C, CYP2E, and CYP2J subfamilies that catalyze the formation of four regioisomeric products, 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid. EETs are produced in brain and perform important biological functions, including protection from ischemic injury. Both light flashes and direct glial stimulation produce vasodilatation mediated by EETs. EETs may be involved in the development of hypertension and endothelial dysfunction in DOCA-salt rats, but not in excessive collagen deposition or electrophysiological abnormalities. EETs have vasodilator and natriuretic effect. Blockade of EET formation is associated with salt-sensitive hypertension. (PMID: 17494091, 17468203, 17434916, 17406062, 17361113) [HMDB]
(Z)-7-((2S,3R)-3-((2Z,5Z)-Undeca-2,5-dienyl)oxiran-2-yl)hept-5-enoic acid
2,3-Thioepoxy Madol
Isocupressic acid
1,3,7-Trimethyl-8-nonylpurine-2,6-dione
13-(3-Pentyloxiran-2-yl)trideca-2,4,6-trienoic acid
Arginylphenylalaninamide
Phenol, 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)-, (E)-
3-Heptadeca-1,3-dienyloxirene-2-carboxylic acid
(8R,9S,10R,13S,14S,17S)-2,2,17-Trihydroxy-10,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one
(ent)-8-alpha-Hydroxy-13(16),14-labdadien-19-oic acid
(E,E,E)-2-(6-Hydroxy-4-methyl-4-hexenylidene)-6,10-dimethyl-5,9-undecadienoic acid
(Z,Z,E)-10-Hydroxy-2,6,10-trimethyl-2,6,11-dodecatrienyl ester 2-methyl-2-butenoic acid
2alpha,9beta-Dihydroxy-3beta,8beta-oxido-1(15)-trinervitene
(E,E)-(-)-2-[2-(2,2-Dimethyl-6-methylenecyclohexyl)ethyl]-1,3-butadiene-1,4-diol diacetate
11,15-Dihydroxy-9,10-seco-ent-labda-8E,13E,(20),triene-3-one
(E,E,E)-1,7-Dihydroxy-2,5,10,14-phytatetraen-13-one
Coralloidin D
(E,E)-2-[2-(2,6,6-Trimethyl-2-cyclohexen-1-yl)ethyl]-1,3-butadiene-1,4-diol diacetate
10beta-Hydroxy-6beta-isobutyryl-furanoeremophilane
Monacolin J
A polyketide that is monacolin L bearing an additional hydroxy substituent at position 8. Monacolin J is an inhibitor of cholesterol biosynthesis, and inhibits the activity of HMG-CoA reductase.
4-(4-Ethylphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile
n,n,n,n-tetrakis(2-hydroxyethyl)adipamide
CONFIDENCE standard compound; INTERNAL_ID 4064 INTERNAL_ID 4064; CONFIDENCE standard compound
3,9-di(cyclohex-3-en-1-yl)-2,4,8,10-tetraoxaspiro[5.5]undecane
(3beta,16alpha)-3,16,18-Trihydroxyandrost-5-en-17-one
anomalone D|methyl 8-((1S,5R)-4-oxo-5-((E)-4-oxopent-2-enyl)oxocyclopent-2-enyl)octanoate
(Z)-13,14-dihydroxy-7-oxo-caryophylla-2(12),5-dien-13-isobutyrate
4-h ydroxy-12-(3 ,4-methylenedioxyphen yl)-2-dodecanone
(3E,5E,9E)-8,11-Diacetoxy-3,7,11-trimethyldodeca-1,3,5,9-tetraene
Butanoyl-15-Hydroxy-3,11(13)-eudesmadien-12-oic acid
(5SR,8SR,9SR,10RS,13SR)-3-hydroxy-16-nor-2-oxodolabr-3-en-15-oic acid
13alpha,16alpha,17-trihydroxy-9alpha-methyl-19,20-di-nor-kauran-4-en-15-one|13??,16??,17-Trihydroxy-9??-methyl-19,20-di-nor-kauran-4-en-15-one
(4I<<)-2EC,15I<<-dihydroxy-19-norkaur-16-en-18-oic acid
(1R,2R,3aR,4S,7aS)-3a,4-dimethyl-4-methylene-2-oxodecahydro-2H-spiro[furan-3,2-indene]-1-yl isobutyrate|bakkenolide I|bakkenolide-I
(ent-2alpha,16alpha)-2-Hydroxy-15-oxo-18-nor-19-kauranoic acid
methyl ent-15,16-dinorisocopal-12-en-13-ol-19-oate
Me ester-(6E,9Z,11E,13E)-9-Formyl-15-hydroxy-6,9,11,13-heptadecatetraenoic acid
methyl 2-(1beta-geranyl-5beta-hydroxy-2-oxocyclohex-3-enyl)acetate|Methyl 2-(1??-geranyl-5??-hydroxy-2-oxocyclohex-3-enyl)acetate
(1R,1aR,1bS,4R,5R,5aS,6aR)-decahydro-5a-methyl-1-(1-methylethyl)-2-methylidenecyclopropa[a]indene-4,5-diyl diacetate|(1R,2R)-diacetoxycycloax-4(15)ene|(1S,3R,4R,5R,6S,9R,10R)-9,10-diacetoxy-1-methyl-4-(1-methylethyl)-7-methylidenetricyclo[4.4.0.0(3.5)]decane
2alpha,3alpha-dihydroxyandrostan-16-one 2beta,19-hemiketal
7beta,8alpha,9alpha,-trihydroxy-20-norisopimara-5(10),15-dien-6-one|smardaesidin F
(4S,5R,9S,10R)-methyl 19-hydroxy-15,16-dinorlabda-8(17),11E-dien-13-oxo-18-oate
(1R,2S,3R,4aR,5R,8aR)-5-[2-(furan-3-yl)ethyl]decahydro-1-(hydroxymethyl)-4a-methyl-6-methylidenenaphthalene-2,3-diol|austroeupatol
(5SR,8SR,9SR,10RS,13SR)-18-hydroxy-16-nor-3-oxodolabr-4(18)en-15-oic acid|tagalsin R
(8R)-2-[(2-methylpropanoyl)oxy]eremophil-7(11)-en-12,8-olide
methyl ent-2,4-seco-15,16-epoxy-4-oxo-3,19-dinorbeyer-15-en-2-oate
2,12-dioxo-A-norclerod-13(16)-en-15-oic acid|pentandranoic acid B
(+)-(1betaH,7E)-6-beta,11beta-dihydroxynorverticilla-4(18),7-diene-10,12-dione|(1R,4E,6S,11R)-1,6-dihydroxy-4,15,15-trimethyl-8-methylidenebicyclo[9.3.1]pentadec-4-ene-2,14-dione|cespihypotin W
6beta-isobutyryloxy-9beta-hydroxy-1beta,10beta-epoxyfuroeremophilane
3,9-dicyclohex-3-enyl-2,4,8,10-tetraoxaspiro[5.5]undecane
CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 1070
oryzalide A
oryzalide B
bhas#10
An (omega-1)-hydroxy fatty acid ascaroside that is ascr#10 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans as well as the sour paste nematode, Panagrellus redivivus.
bhos#10
An omega-hydroxy fatty acid ascaroside that is oscr#10 in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.
4-(3-HYDROXY-2-PHENYL-PROPYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
Denbufylline
D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
3-N-BOC-AMINO-1-[2-AMINO-1-(2-AMINO-PHENYL)-ETHYL]-PYRROLIDINE
3-N-BOC-AMINO-1-[2-AMINO-1-(3-AMINO-PHENYL)-ETHYL]-PYRROLIDINE
3-N-BOC-1-[2-AMINO-1-(4-AMINO-PHENYL)-ETHYL]-PYRROLIDINE
methyl 3-[4-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y l)phenyl]propanoate
2-(Boc-Amino)pyridine-3-boronic acid pinacol ester
(S)-TERT-BUTYL 4-BENZYL-2-(2-HYDROXYETHYL)PIPERAZINE-1-CARBOXYLATE
(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)furan-2-yl)boronic acid
tert-Butyl (5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)carbamate
tert-butyl 4-((benzylamino)Methyl)-4-hydroxypiperidine-1-carboxylate
1-((1,1-DIMETHYLETHOXY)CARBONYL)-4-(3-(PROPYLAMINO)-2-PYRIDYL)-PIPERAZINE
1-((1,1-DIMETHYLETHOXY)CARBONYL)-4-(3-((1-METHYLETHYL)AMINO)-2-PYRIDYL)PIPERAZINE
TERT-BUTYL (3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-4-YL)CARBAMATE
METHYL 3-ISOPROPOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZOATE
1,3-Bis[(2,2-dimethyl-1,3-dioxan-5-yl)oxy]-2-propanol
tert-butyl N-[1-(benzylamino)-4-methyl-1-oxopentan-2-yl]carbamate
tert-butyl [3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl] carbonate
4-Fluorophenyl trans-4-heptyl-1-cyclohexanecarboxylate
tert-Butyl 2,7-diazaspiro[4.5]decane-2-carboxylate
(4-((4-(TERT-BUTOXYCARBONYL)PIPERAZIN-1-YL)METHYL)PHENYL)BORONIC ACID
(3beta,7alpha,15alpha)-3,7,15-Trihydroxy-androst-5-en-17-one
tert-butyl 4-[[4-(aminomethyl)phenyl]methoxy]piperidine-1-carboxylate
1-Ethyl-3-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea
4-[6-(Guanidino)pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester
1,2-Bis(2-(N,N-Dimethylamino)EthoxyDimethylsilyl)Ethane
N-tert-Butyl-2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
N-butyl-2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
2-(4-methyl-5-oxo-4-propan-2-yl-1H-imidazol-2-yl)pyridine-3-carboxylic acid: propan-2-amine
tert-butyl [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl] carbonate
Phenol,4,4-(octahydro-4,7-methano-5H-inden-5-ylidene)bis-
2-t-Butoxycarboxyphenylboronic acid, pinacol ester
1-(5-SEC-BUTYL-2-(METHOXYMETHOXY)PHENYL)NAPHTHALENE
(3R,8R)-8-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxynonanoic acid
(3R)-9-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxynonanoic acid
1-Amino-15-oxo-4,7,10-trioxa-14-azaoctadecan-18-oic acid
1-[Bis(prop-2-enyl)amino]-3-(9-carbazolyl)-2-propanol
12alpha-Fluoro-11beta,17beta-dihydroxyandrosta-1,4-dien-3-one
60410-89-1
9,13,13-Trimethyl-3-oxo-2-oxatetracyclo[7.6.1.01,6.012,15]hexadecane-5-carboxylic acid
5-(6-HYDROXY-2,5,7,8-TETRAMETHYL-CHROMAN-2-YL)-2-METHYL-PENTANOIC ACID
Carbamic acid, ((1S)-2-methyl-1-((((1R)-1-(4-methylphenyl)ethyl)amino)carbonyl)propyl)-, 1-methylethyl ester
(1R,8R,9S,13R,15S)-8,15-dihydroxy-5,5,9-trimethyl-14-methylidene-7-oxatetracyclo[11.2.1.01,10.04,9]hexadecan-6-one
2-[(3aS,5aS,6S,9aS,9bS)-6-acetyl-3a,6-dimethyl-3-oxo-1,2,4,5,5a,7,8,9,9a,9b-decahydrocyclopenta[a]naphthalen-7-yl]acetic acid
11-Meo-fes
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
4-[(Z)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenol
D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids
(8R,9S,10R,13S,14S,17S)-2,2,17-Trihydroxy-10,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one
Atractyligenin
A diterpenoid isolated from coffee silverskin. It inhibits cutaneous photoaging.
N-(2-furylmethyl)-3-[(2s,5as,8ar)-1-methyl-5-oxodecahydropyrrolo[3,2-e][1,4]diazepin-2-yl]propanamide
2,4-Dihydroxy-3-methyl-6-(2-oxoundecyl)benzaldehyde
A dihydroxybenzaldehyde that is 2,4-dihydroxybenzaldehyde in which the hydrogens at positions 3 and 6 have been replaced by a methyl and 2-oxoundecyl groups, respectively.
3-[cyclopropylmethyl(propyl)amino]-N-(3,5-dimethoxyphenyl)propanamide
isopropylammonium 2-[(R)-4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl]nicotinate
isopropylammonium 2-[(S)-4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl]nicotinate
(9R,17S)-9-fluoro-11,17-dihydroxy-10,17-dimethyl-2,6,7,8,11,12,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
(3R,9R)-9-fluoro-10,17,17-trimethyl-1,2,3,6,7,8,11,12,15,16-decahydrocyclopenta[a]phenanthrene-3,11-diol
(5S,9S,17R)-9-fluoro-17-hydroxy-10,13,17-trimethyl-1,2,4,5,6,7,8,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(5R,9S,17R)-9-fluoro-17-hydroxy-10,13,17-trimethyl-1,2,4,5,6,7,8,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(9S,17R)-9-fluoro-17-hydroxy-10,13,17-trimethyl-1,2,4,5,6,7,8,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
1,2-Benzenedicarboxylic acid isopropyl 2-ethylhexyl ester
3,4-Dihydro-2,5,7,8-tetramethyl-6-hydroxy-2H-1-benzopyran-2-propanoic acid isopropyl ester
(1R,6R,9R)-9,13,13-trimethyl-3-oxo-2-oxatetracyclo[7.6.1.01,6.012,15]hexadecane-5-carboxylic acid
2,3-dihydroxypropyl (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
[1-Carboxy-3-(2-hydroxy-3-pentanoyloxypropoxy)propyl]-trimethylazanium
Isopropyl (3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl)carbamate
5H-1b,10-Methanooxireno[6,7]cyclohepta[1,2-h][2]benzopyran-5-one, dodecahydro-7-hydroxy-4,4,7a,10a-tetramethyl-, (1aS,1bS,3aR,7S,7aR,7bS,10S,10aR)-
A-381393
A-381393 is a potent, selective, brain penetrate dopamine D4 receptor antagonist, with Kis of 1.5, 1.9 and 1.6 nM for human dopamine D4.4, D4.2, and D4.7 receptor, respectively, >2700-fold selectivity over D1, D2, D3 and D5 dopamine receptors. A-381393 shows moderate affinity for 5-HT2A (Ki, 370 nM)[1].
15,16-dihydroxy-5-methyl-17-oxapentacyclo[14.2.1.0¹,¹³.0²,¹⁰.0⁵,⁹]nonadecan-7-one
7-hydroxy-2,4a,8,8a-tetramethyl-6-oxo-1,3,4,4b,5,9,10,10a-octahydrophenanthrene-2-carboxylic acid
9-hydroxy-6,10-dimethyl-3-methylidene-4-(2-methylpropoxy)-3ah,4h,5h,8h,9h,11ah-cyclodeca[b]furan-2-one
4-hydroxy-5a-methyl-3,9-dimethylidene-6-(2-methylpropoxy)-octahydronaphtho[1,2-b]furan-2-one
(1r,9r,10r,13s,14s)-13,14-dihydroxy-14-(hydroxymethyl)-5,10-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-4-en-15-one
(1s,4ar,5s,8ar)-5-(3-carboxy-3-methylprop-2-en-1-yl)-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylic acid
(4s,4as,5z,7r,8s)-8-(acetyloxy)-4,4a,6-trimethyl-3,4,7,8,9,10-hexahydro-2h-benzo[8]annulen-7-yl acetate
methyl 8-[(1r,5e)-1-hydroxy-4-oxo-5-[(2e)-pent-2-en-1-ylidene]cyclopent-2-en-1-yl]octanoate
5-hydroxy-2-methylidene-4-[(6z)-tetradec-6-enoyl]furan-3-one
(1e,3e)-4-(acetyloxy)-2-{2-[(1r)-2,2-dimethyl-6-methylidenecyclohexyl]ethyl}buta-1,3-dien-1-yl acetate
(4r,5r,7r,9r,10r,13s,14r)-14-formyl-7-hydroxy-9-methyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
(1r,5s,7s)-7-(acetyloxy)-2,8-dimethylidene-5-(prop-1-en-2-yl)cyclodecyl acetate
(4s,4as,7r,8s)-8-(acetyloxy)-4,4a,6-trimethyl-3,4,7,8,9,10-hexahydro-2h-benzo[8]annulen-7-yl acetate
5-[(1s,3ar,4s,5r,7ar)-1,4,5,7a-tetramethyl-2-oxo-hexahydroinden-4-yl]-3-methylidene-4-oxopentanoic acid
9,10-dihydroxyheptadec-1-en-11,13-diyn-8-yl acetate
5-[(1r,4s,4as,6s,8r,8ar)-6-(hydroxymethyl)-4-methoxy-2,8-dimethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]penta-2,4-dienoic acid
methyl 2-{4-acetyl-5,9-dimethyl-11-oxatetracyclo[7.3.1.0¹,⁶.0¹⁰,¹²]tridecan-5-yl}acetate
(4s,4as,7s,8s)-8-(acetyloxy)-4,4a,6-trimethyl-3,4,7,8,9,10-hexahydro-2h-benzo[8]annulen-7-yl acetate
4-(acetyloxy)-2-[2-(2,6,6-trimethylcyclohex-2-en-1-yl)ethyl]buta-1,3-dien-1-yl acetate
(2s,4as,4br,8z,8as,10as)-8-(hydroxymethylidene)-2,4a,8a-trimethyl-7-oxo-octahydro-1h-phenanthrene-2-carboxylic acid
6,9,10-trimethyl-8-(2-methylpropoxy)-4,14-dioxatetracyclo[7.5.0.0¹,¹³.0³,⁷]tetradeca-3(7),5-dien-2-ol
(1e,3e)-4-(acetyloxy)-2-{2-[(1s)-2,6,6-trimethylcyclohex-2-en-1-yl]ethyl}buta-1,3-dien-1-yl acetate
({5-butyl-7-oxo-decahydropyrrolo[2,1-j]quinolin-3-yl}methyl)sulfanylcarbonitrile
10,11-dihydroxy-8,15,15-trimethyl-4-methylidenebicyclo[9.3.1]pentadec-7-ene-6,12-dione
(1r,4s,8r,9s,10r,13r,14s)-8-hydroxy-5,5,9,14-tetramethyl-7,15-dioxapentacyclo[11.3.1.0¹,¹⁰.0⁴,⁹.0¹⁴,¹⁶]heptadecan-6-one
2-hydroxy-15-oxo-18-nor-19-kauranoic acid
{"Ingredient_id": "HBIN005716","Ingredient_name": "2-hydroxy-15-oxo-18-nor-19-kauranoic acid","Alias": "NA","Ingredient_formula": "C19H28O4","Ingredient_Smile": "NA","Ingredient_weight": "320.42","OB_score": "NA","CAS_id": "51107-83-6","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8628","PubChem_id": "NA","DrugBank_id": "NA"}
3,16,18-trihydroxyandrost-5-en-17-one
{"Ingredient_id": "HBIN006938","Ingredient_name": "3,16,18-trihydroxyandrost-5-en-17-one","Alias": "NA","Ingredient_formula": "C19H28O4","Ingredient_Smile": "NA","Ingredient_weight": "320.42","OB_score": "NA","CAS_id": "85922-89-0","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8449","PubChem_id": "NA","DrugBank_id": "NA"}
